EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

One‐Year Substantia Nigra R2* Changes across Parkinson's Disease Stages

Calvin Coussediere, Bruno Pereira, David Devos, Stéphane Lehéricy, Patrice Peran iD, Elodie Durand, Carine Chassain, Jean Luc Houeto, Isabelle Benatru, Olivier Colin, Olivier Rascol, Fabienne Ory-Magne und 18 weitere

Movement Disorders · 2026-08 · 41 (8) · 2117-2132

DOI: 10.1002/mds.70331 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Movement Disorders, online erschienen am 27.04.2026. Verfasst von Calvin Coussediere und 29 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department and NS-PARK/FCRIN Network, University Clermont Auvergne, Clermont-Ferrand University Hospital, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Parkinson Disease, Substantia Nigra. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: French Ministry of Health (Programme Hospitalier de Recherche Clinique, PHRC), Fédération pour la Recherche sur le Cerveau (FRC)" and "NS-PARK F-CRIN Network (French Clinical Research Infrastructure Network), Association France Parkinson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Magnetic resonance imaging (MRI) relaxometry using measurement is a promising non‐invasive marker of brain iron‐related changes in Parkinson's disease (PD). Although longitudinal susceptibility MRI studies have demonstrated progression over time, the stage‐dependent dynamics of changes across the full spectrum of PD duration remain incompletely characterized.

Objectives

The goal was to assess 1‐year longitudinal changes across PD stages within a multicenter framework, compared with healthy controls (HC).

Methods

In this prospective multicenter study, 95 PD patients and 65 age‐ and sex‐matched HC underwent 3 T MRI and clinical evaluation at baseline and 1 year. PD patients were stratified by disease duration (15 years). values were extracted from basal ganglia regions, focusing primarily on the substantia nigra (SN). Motor and non‐motor assessments, performed in the on ‐medication state, included the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale, Montreal Cognitive Assessment, and mood/apathy scales.

Results

SN increased significantly over 1 year across PD patients (+5% within‐group) and HC (+2% within‐group), resulting in a +3% greater longitudinal change in PD versus HC ( P < 0.001). Larger SN changes were observed in patients with longer disease duration ( r = 0.28; P = 0.006). Significant changes were also detected in other basal ganglia regions. No significant change in motor or non‐motor disability in the on ‐medication state was observed over 1 year.

Conclusions

S N increased over 1 year in PD across disease stages, with larger changes in more advanced patients and no evidence of an early plateau. These findings support the potential of as a sensitive imaging marker of PD progression over short intervals. © 2026 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseSubstantia NigraHumansFemaleMagnetic Resonance ImagingMaleDisease ProgressionAgedMiddle AgedProspective StudiesLongitudinal Studies

Stichwörter der Autor:innen

MRI relaxometryParkinson's diseaseR2*biomarkerlongitudinal studysubstantia nigra

Autor:innen und Institutionen

  • Neurology Department and NS-PARK/FCRIN Network, University Clermont Auvergne, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
  • Biostatistics Unit (DRCI), Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
  • Department of Medical Pharmacology, Expert Centre of Parkinson's Disease, University of Lille, LilNCog, Lille Neuroscience and Cognition, INSERM UMR-S1172, CHU de Lille LICEND COEN Center Lille and NS-PARK/FCRIN Network…
  • Sorbonne Université, Institut du Cerveau - ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127, CNRS 7225; Département de Neuroradiologie and NS-PARK/FCRIN Network; Hôpital Pitié-Salpêtrière, Paris, France.
  • ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, INSERM, UPS, Toulouse, France.
  • Service de Neurologie, Centre Expert Parkinson, and NS-PARK/FCRIN Network, INSERM, CHU de Poitiers, Université de Poitiers, Centre d'Investigation Clinique CIC1402, Poitiers, France.

ORCID-Profile: Patrice Peran, Wassilios G Meissner, Jean-Marie Bonny

Förderung

  • French Ministry of Health (Programme Hospitalier de Recherche Clinique, PHRC)
  • Fédération pour la Recherche sur le Cerveau (FRC)" and "NS-PARK F-CRIN Network (French Clinical Research Infrastructure Network)
  • Association France Parkinson

Zitieren

APA

Coussediere, C., Pereira, B., Devos, D., Lehéricy, S., Peran, P., Durand, E., Chassain, C., Houeto, J. L., Benatru, I., Colin, O., Rascol, O., Ory-Magne, F., Brefel-Courbon, C., Maindreville, A. D., Vidailhet, M., Corvol, J. C., Frismand, S., Schmitt, E., Defebvre, L., …, & MPI‐R2* study group (2026). One‐Year Substantia Nigra R2* Changes across Parkinson's Disease Stages. Movement Disorders, 41(8), 2117-2132. https://doi.org/10.1002/mds.70331

Vancouver

Coussediere C, Pereira B, Devos D, Lehéricy S, Peran P, Durand E, et al. One‐Year Substantia Nigra R2* Changes across Parkinson's Disease Stages. Movement Disorders. 2026;41(8):2117-2132. doi:10.1002/mds.70331

BibTeX
@article{Coussediere2026,
  author = {Coussediere, Calvin and Pereira, Bruno and Devos, David and Lehéricy, Stéphane and Peran, Patrice and Durand, Elodie and Chassain, Carine and Houeto, Jean Luc and Benatru, Isabelle and Colin, Olivier and Rascol, Olivier and Ory-Magne, Fabienne and Brefel-Courbon, Christine and Maindreville, Anne Doé de and Vidailhet, Marie and Corvol, Jean-Christophe and Frismand, Solène and Schmitt, Emmanuelle and Defebvre, Luc and Carriere, Nicolas and Meissner, Wassilios G and Boraud, Thomas and Remy, Philippe and Moro, Elena and Thobois, Stéphane and Geny, Christian and Bonny, Jean-Marie and Durif, Franck and Marques, Ana and MPI‐R2* study group, MPI‐R2* study group},
  title = {One‐Year Substantia Nigra R2* Changes across Parkinson's Disease Stages},
  journal = {Movement Disorders},
  year = {2026},
  volume = {41},
  number = {8},
  pages = {2117--2132},
  doi = {10.1002/mds.70331}
}
Kostenlos starten →